CH644269A5 - Composition a usage externe a base de colostrum. - Google Patents
Composition a usage externe a base de colostrum. Download PDFInfo
- Publication number
- CH644269A5 CH644269A5 CH505380A CH505380A CH644269A5 CH 644269 A5 CH644269 A5 CH 644269A5 CH 505380 A CH505380 A CH 505380A CH 505380 A CH505380 A CH 505380A CH 644269 A5 CH644269 A5 CH 644269A5
- Authority
- CH
- Switzerland
- Prior art keywords
- colostrum
- composition according
- composition
- tears
- lactotransferrin
- Prior art date
Links
- 210000003022 colostrum Anatomy 0.000 title claims description 29
- 235000021277 colostrum Nutrition 0.000 title claims description 29
- 239000000203 mixture Substances 0.000 title claims description 27
- 239000003889 eye drop Substances 0.000 claims description 9
- 108010063045 Lactoferrin Proteins 0.000 claims description 8
- 102000012174 Lactotransferrin Human genes 0.000 claims description 8
- 238000010790 dilution Methods 0.000 claims description 4
- 239000012895 dilution Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 230000001228 trophic effect Effects 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108091006975 Iron transporters Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000012404 Orosomucoid Human genes 0.000 description 1
- 108010061952 Orosomucoid Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 208000030452 Transient pseudohypoaldosteronism Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000001420 bacteriolytic effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/986—Milk; Derivatives thereof, e.g. butter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Developmental Biology & Embryology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7917118A FR2460135A1 (fr) | 1979-07-02 | 1979-07-02 | Composition a usage externe a base de colostrum |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH644269A5 true CH644269A5 (fr) | 1984-07-31 |
Family
ID=9227385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH505380A CH644269A5 (fr) | 1979-07-02 | 1980-07-01 | Composition a usage externe a base de colostrum. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4342747A (cg-RX-API-DMAC7.html) |
| JP (1) | JPS5653612A (cg-RX-API-DMAC7.html) |
| BE (1) | BE883935A (cg-RX-API-DMAC7.html) |
| CH (1) | CH644269A5 (cg-RX-API-DMAC7.html) |
| DE (1) | DE3024623A1 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2460135A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB2052979B (cg-RX-API-DMAC7.html) |
| IT (1) | IT1130487B (cg-RX-API-DMAC7.html) |
| MA (1) | MA18877A1 (cg-RX-API-DMAC7.html) |
| NL (1) | NL8003802A (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0188501A1 (en) * | 1984-07-13 | 1986-07-30 | Economix Közgazdasz Egyetemi Kisszövetkezet | Process for the preparation of a pharmaceutical composition influencing the tissue metabolism and having a regenerating action |
| FR2627386A1 (fr) * | 1988-02-22 | 1989-08-25 | Serge Liotet | Composition a usage externe destinee a l'administration oculaire |
| FR2628973B1 (fr) | 1988-03-25 | 1990-11-16 | Gattefosse Ets Sa | Composition cosmetique ou pharmaceutique a usage cutane, et procede pour la preparation d'une telle composition |
| DE3924420A1 (de) * | 1989-07-24 | 1991-01-31 | Biotest Pharma Gmbh | Verfahren zur herstellung eines immunglobulin-praeparates aus kolostrum |
| DE4026365A1 (de) | 1990-08-21 | 1992-02-27 | Biotest Pharma Gmbh | Sterilfiltrierte kolostralmilch |
| ES2096663T3 (es) * | 1990-11-13 | 1997-03-16 | Santen Pharmaceutical Co Ltd | Agente terapeutico para lesiones de la cornea. |
| FR2676331B1 (fr) * | 1991-05-17 | 1993-09-03 | Opsia Pharma | Milieu de conservation d'organes, de tissus ou de cellules. |
| ES2102813T3 (es) * | 1993-01-26 | 1997-08-01 | Horse Vitality Ltd | Composiciones farmaceuticas y dermocosmeticas que contienen calostro equino. |
| WO1995000155A1 (en) * | 1993-06-23 | 1995-01-05 | Viable Bioproducts Ltd. | Method for the improvement of wound healing and compositions therefor |
| DK0743060T3 (da) * | 1995-04-28 | 2003-03-17 | Sara Lee De Nv | Anvendelse af tandplejemidler indeholdende bovint colostrum |
| JP3118584B2 (ja) * | 1995-05-08 | 2000-12-18 | 参天製薬株式会社 | 術後乱視予防剤 |
| DE19537297A1 (de) * | 1995-07-07 | 1997-01-09 | Paerson & Co Gmbh & Co | Kosmetische Präparate mit Wachstumsfaktoren hergestellt aus Milch und Kolostrum von Kühen und Stuten |
| AUPN642795A0 (en) | 1995-11-08 | 1995-11-30 | Northfield Laboratories Pty Ltd | Dairy compositions and methods of preparing same |
| US20030203839A1 (en) * | 1999-10-29 | 2003-10-30 | Kruzel Marian L. | Immune enhancing composition containing lactoferrin |
| US20060013889A1 (en) * | 2004-07-16 | 2006-01-19 | Playford Raymond J | Colostrum-based treatment for irritable bowel syndrome |
| US7426440B2 (en) * | 2004-09-24 | 2008-09-16 | Nutritional Bioscience Ltd. | Repair and protection factor scoring method for bioactive agents |
| US20060068022A1 (en) * | 2004-09-29 | 2006-03-30 | Playford Raymond J | Bioactive agent compositions for repair of cell injuries |
| US20100068213A1 (en) * | 2007-02-20 | 2010-03-18 | N.V. Nutricia | Selected colostrum for treatment of intestinal barrier function disorders |
| WO2013098333A1 (en) * | 2011-12-30 | 2013-07-04 | Bionest Ltd. | Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins c3a/c4a, immunoglobulins and chemotactic factors |
| ITMI20112440A1 (it) * | 2011-12-30 | 2013-07-01 | Bionest Ltd | Formulazioni contenenti citochine, fattori di crescita, chemiotattici, antibatterici ed eventualmente immunoglobuline e complemento, per la terapia topica delle lesioni corneali |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB467825A (en) * | 1935-12-23 | 1937-06-23 | Gyula Groh | Process for the production of substances for promoting the growth of backward infants |
| GB734117A (en) * | 1952-04-28 | 1955-07-27 | Evagoras Joannou Georgiou | Preparation of a substance for the treatment of malignant tumours |
| FR2360313A1 (fr) * | 1976-08-03 | 1978-03-03 | Fabre Sa Pierre | Compositions pharmaceutiques utiles notamment pour le traitement de la seborrhee |
| CH627079A5 (en) * | 1977-04-15 | 1981-12-31 | Nestle Sa | Process for preparing a protein concentrate containing immunological factors of milk origin |
-
1979
- 1979-07-02 FR FR7917118A patent/FR2460135A1/fr active Granted
-
1980
- 1980-06-19 MA MA19075A patent/MA18877A1/fr unknown
- 1980-06-20 BE BE0/201117A patent/BE883935A/fr not_active IP Right Cessation
- 1980-06-23 GB GB8020439A patent/GB2052979B/en not_active Expired
- 1980-06-26 US US06/163,189 patent/US4342747A/en not_active Expired - Lifetime
- 1980-06-30 DE DE19803024623 patent/DE3024623A1/de active Granted
- 1980-07-01 CH CH505380A patent/CH644269A5/fr not_active IP Right Cessation
- 1980-07-01 JP JP8988780A patent/JPS5653612A/ja active Granted
- 1980-07-01 IT IT68031/80A patent/IT1130487B/it active
- 1980-07-01 NL NL8003802A patent/NL8003802A/nl not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| FR2460135B1 (cg-RX-API-DMAC7.html) | 1982-11-19 |
| BE883935A (fr) | 1980-10-16 |
| DE3024623A1 (de) | 1981-01-22 |
| GB2052979A (en) | 1981-02-04 |
| US4342747A (en) | 1982-08-03 |
| DE3024623C2 (cg-RX-API-DMAC7.html) | 1989-10-26 |
| IT1130487B (it) | 1986-06-11 |
| JPS5653612A (en) | 1981-05-13 |
| GB2052979B (en) | 1984-02-29 |
| FR2460135A1 (fr) | 1981-01-23 |
| IT8068031A0 (it) | 1980-07-01 |
| JPH021127B2 (cg-RX-API-DMAC7.html) | 1990-01-10 |
| NL8003802A (nl) | 1981-01-06 |
| MA18877A1 (fr) | 1980-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH644269A5 (fr) | Composition a usage externe a base de colostrum. | |
| Clark et al. | Hydration and chronic kidney disease progression: a critical review of the evidence | |
| US6759056B2 (en) | Mixture for transdermal delivery of low and high molecular weight compounds | |
| US7300666B2 (en) | Mixture for transdermal delivery of low and high molecular weight compounds | |
| CA2227977A1 (fr) | Utilisation dans une composition d'un extrait d'au moins une labiee | |
| EP1392352A1 (fr) | Utilisation d'un antioxydant pour le traitement et/ou la prevention des affections oculaires de surface | |
| JP4532900B2 (ja) | 細菌またはウイルス感染症の予防または治療における乳清アポタンパク質の使用 | |
| DE60200256D1 (de) | Fraktion basischer Proteine aus Milch als Wirkstoff zur Reduktion von Bluthochdruck | |
| Stoof et al. | Does fish oil protect renal function in cyclosporin‐treated psoriasis patients? | |
| CA2540539C (en) | A mixture for transdermal delivery of low and high molecular weight compounds comprising an ethoxylated oil | |
| EP0970118B1 (fr) | Inhibiteurs specifiques de la lipase pancreatique et leurs applications | |
| US20090069218A1 (en) | Pharmaceutical compositions comprising casein derived peptides and methods of use thereof | |
| US8895080B2 (en) | Compositions and kits for ocular treatment | |
| FR2503563A1 (fr) | Composition pour collyre a base de sulfate de chondroitine a | |
| FR2627386A1 (fr) | Composition a usage externe destinee a l'administration oculaire | |
| EP0083261B1 (fr) | Composition thérapeutique, à base d'inosine monophosphaté, pour le traitement des troubles d'accommodation de l'oeil | |
| EP1303296B1 (fr) | Composition contenant une proteine complexant le fer et un precurseur du metabolisme du monoxyde d'azote et/ou un donneur chimique de monoxyde d'azote et utilisations | |
| EP0182696B1 (fr) | Médicament insoluble administré localement dans l'oreille | |
| EP0615757A1 (fr) | Composition thérapeutique nouvelle ayant un effet immunostimulant | |
| WO2016051179A1 (en) | Composition comprising lactoferrine and methods of treatment | |
| FR2647784A1 (fr) | Association de vitamine a a dose physiologique et de differents principes actifs ayant une activite therapeutique | |
| EP0722952B1 (fr) | Fraction sérocolostrale hypoallergénique à forte activité anticorps, utilisation et procédé de fabrication d'une telle fraction | |
| EP1296667B1 (fr) | Composes pour la prevention et/ou le traitement des urticaires | |
| AU2012200889A1 (en) | Pharmaceutical compositions comprising casein derived peptides and methods of use thereof | |
| BE886485A (fr) | Composition d'acide 2-(3-benzoylphenyl)-propionique (ketoprofene, dci) micro-encapsule pour usage therapeutique oral a action prolongee |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |